|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] The Canadian drug market remains robust and is considered by BMI to be one of the best environments in the world for a drugmaker to operate in. In 2006, the pharmaceutical market reached a value of US$18.6bn, and, going forward, BMI expects sales to be powered by generics. Over the next five years BMI forecasts a compound annual growth rate (CAGR) of 7.68% bringing the total value of the generics sector to US$5.5bn. This compares to an overall market CAGR of 5.07%. However, as discussed in detail in BMI's Q108 Canada Pharmaceuticals & Healthcare Report, generic sales are being buoyed by high prices, despite the presence of a salubrious and competitive manufacturing industry. The primary problem appears to be the failure of pharmacies to pass on discounts offered by drugmakers to the end-payer. A study by the Patented Medicines Price Review Board (PMRB) in June 2006 concluded that retail prices for generic drugs were higher in Canada than in 10 out of 11 comparable markets. However the failure of pharmacies to address the situation, means that the authorities will probably be forced to. Both Ontario and Quebec have recently lowered the maximum price ceiling for generics drugs, in order to combat perceived price gouging. Meanwhile, it has been a busy quarter in terms of company activity. Probably the biggest event was the US$900mn acquisition of Canadian biotech Aspreva by Swiss pharmaceutical producer and wholesaler Galenica. The purchase is one of the largest ever in the Canadian pharmaceutical sector and should provide a ringing endorsement for Canada's biotech industry, often criticised as a difficult environment to work in. Rather than developing novel drugs, Aspreva concentrates on finding new indications for existing drugs, often in neglected or rare disease areas. In BMI's new methodology for Business Environment Rankings - which gives stronger emphasis to the regulatory environment, and also factors in country-specific economic and political indicators – Canada ranks in second position, in the Americas region and third globally. This is primarily because of excellent Country Risk Indicators, including low corruption and a stable political environment, solid growth in the pharmaceutical market, and a generous government reimbursement system.
Contents[TOP] Executive SummaryCanada Pharmaceuticals & Healthcare Industry SWOT Canada Political SWOT Canada Economic SWOT Chapter 1 - Pharmaceutical Business Environment RatingsTable: Pharmaceutical Business Environment Rankings Limits To Potential Returns Risks To Realisation Of Returns Chapter 2 - Canada - Market SummaryChapter 3 - Regulatory RegimeIntellectual Property Developments Pricing And Reimbursement Issues Ontario Breaks The Mould Chapter 4 - Industry DevelopmentsProduct Approvals And Launches Pharmaceutical Re-import Policy Company Activity National Pharmaceuticals Strategy Generics Sector Table: Foreign-To-Canadian Price Ratios, 2005 Research And Development Sector Pharmacy Sector Chapter 5 - Industry Forecast ScenarioOverall Market Forecast Table: Canada: Drug Market Indicators Key Growth Factors - Industry Table: Canadian Health Expenditure Indicators Key Growth Factors - Macroeconomic Table: Canada - Economic Activity OTC Market Forecast Table: Canadian OTC Drugs Market Forecast Indicators (US$mn unless otherwise stated) Generics Market Forecast Table: Canadian Generics Market Indicators Patented Market Forecast Table: Canadian Patented Market Indicators Export/Import Forecasts Table: Sectoral Trade Indicators (US$mn) Other Healthcare Data Forecasts Table: Canadian Socio-demographic Indicators Chapter 6 - Competitive LandscapeTable: Canada's Leading Generics Firms, 2006 Chapter 7 - Company ProfilesLeading Multinational Manufacturers Pfizer Merck & Co GlaxoSmithKline Sanofi-Aventis Novartis Indigenous Manufacturers Apotex Chapter 8 - BMI Forecast ModellingHow We Generate Our Industry Forecasts Pharmaceutical Industry Pharmaceutical Business Environment Ratings Methodology Ratings Overview Table: Pharmaceutical Business Environment Indicators Weighting Table: Weighting Of Components Sources |
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Americas Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.
|
||||||||||||||||
Network of American Pharmaceuticals & Healthcare Sources[TOP] BMI's American Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceuticals industry associations, chambers of commerce and company reports. Information sources include:
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||